ReviewJournal of thoracic disease2020
Autoimmune disorders and paraneoplastic syndromes in thymoma.
Review in Journal of thoracic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Interplay between triglyceride-glucose index and cardiovascular events in hypertensive patients with controlled blood pressure (SBP<140 mmHg): insights from the SPRINT trial.Frontiers in endocrinology · 2025Trial
- Lichenoid variant of paraneoplastic pemphigus arising 1 week after thymoma resection.JAAD case reports · 2026Article
- Matrine suppresses thymoma stemness and apoptosis via YTH N6-methyladenosine RNA binding protein 1 and Wnt/β-catenin signaling.3 Biotech · 2026Article
- Uniportal midline subxiphoid thymectomy: Our experience from a single oncology centre in India.Lung India : official organ of Indian Chest Society · 2026Article
- Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors.NPJ precision oncology · 2026Article
- Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy.Cancer immunology, immunotherapy : CII · 2026Review
- Cutaneous paraneoplastic syndromes in cats: a comparative clinical review.Journal of feline medicine and surgery · 2026Review
- Immune remodeling after thymectomy in patients with anti-AChR antibodies.Frontiers in immunology · 2026Article
- Role of radiotherapy in thymoma and thymic carcinoma: a narrative review.Mediastinum (Hong Kong, China) · 2026Review
- Systemic therapy for advanced thymic epithelial tumors: a narrative review of current evidence and perspectives.Mediastinum (Hong Kong, China) · 2026Review
- Case report: Thymoma-associated GAD65 autoimmunity: a unifying mechanism for multi-organ injury involving nervous, endocrine, and renal systems.Frontiers in immunology · 2026Article
- A rare presentation of CASPR2-associated Morvan syndrome overlapping with GM1-positive AMSAN: a case report.Frontiers in immunology · 2026Article
- Immune-Mediated Multilineage Cytopenias in Thymoma: A Retrospective Case Series.Thoracic cancer · 2026Article
- Myasthenia gravis with thymoma-associated CRMP5/CV2 antibody-positive paraneoplastic neurological syndrome: a case report and literature review.Frontiers in immunology · 2026Review
- Case Report: Recurrent metastatic thymoma-associated multiple paraneoplastic syndromes: myasthenia gravis, dysgeusia, and acute intestinal pseudo-obstruction.Frontiers in oncology · 2026Article
- Article
- Behçet Disease and Cognitive Impairment: A Case Study of an Overlooked Symptom.The American journal of case reports · 2025Article
- Current Clinical Paradigm and Therapeutic Advancements in Thymic Malignancies: A Narrative Review.Cancers · 2025Review
- Myasthenia gravis complicated by intestinal pseudo-obstruction: a case report and literature review.BMC neurology · 2025Review
- Regressed anterior mediastinal nodule secondary to removal of dental crowns.Journal of surgical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymomas are counted among the rare tumour entities which are associated with autoimmune disorders (AIDs) and paraneoplastic syndromes (PNS) far more often than other malignancies. Through its complex immunological function in the context of the selection and maturation of T cells, the thymus is at the same time highly susceptible to disruptive factors caused by the development and growth of thymic tumours. These T cells, which are thought to develop to competent immune cells in the thymus, can instead adopt autoreactive behaviour due to the uncontrolled interplay of thymomas and become the trigger for AID or PNS affecting numerous organs and tissues within the human body. While myasthenia gravis is the most prevalent PNS in thymoma, numerous others have been described, be they related to neurological, cardiovascular, gastrointestinal, haematological, dermatological, endocrine or systemic disorders. This review article sheds light on the pathophysiology, epidemiology, specific clinical features and therapeutic options of the various forms as well as courses and outcomes of AID/PNS in association with thymomas. Whenever suitable and backed by the limited available evidence, the perspectives from both the thymoma and the affected organ/tissue will be highlighted. Specific issues addressed are the prognostic significance of thymectomy on myasthenia gravis and other thymoma-associated AID/PND and further the impact and safety of immunotherapies on AID and PND relating to thymomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.